retatrutide triple agonist phase 2 obesity trial Severe Shows 30% Weight Loss Retatrutide, a TRIPLE agonist (GLP1,

Its the first once-daily GLP-1 pill that has shown results similar to injectable versions

"Not only can they decrease the user's BMI but they also carry metabolic and cardiovascular benefits as well

In a randomized clinical trial published in JAMA Psychiatry, semaglutide reduced alcohol craving and improved some drinking outcomes versus placebo in adults with alcohol use disorder

G., Baker, C., Do, D., & Stucky, N

Insurance coverage isnt forever

Cell Proliferation Analysis The cell proliferation analysis was performed using Cell Counting Kit8 (CCK8) assay, imagebased cell proliferation analysis, and clone formation assay